Pierre Fabre Sa 2025 AR2
The report highlights Pierre Fabre Laboratories' achievements in 2024, including surpassing the –3 billion revenue milestone driven by international growth and oncology innovations. The company advanced its 'Conquest 2025' strategic plan, focusing on therapeutic innovation, operational excellence, and ecological transition. Key environmental milestones include a 25% reduction in greenhouse gas emissions (Scopes 1 and 2) and a 37% reduction in water consumption in France compared to baseline years. Additionally, the company invested –219 million in R&D, with a strong focus on oncology, and continued to support access to healthcare through the Fondation Pierre Fabre.
Company: Pierre Fabre Sa
Year: 2025
Type: AR2
Pages: 48
Pierre Fabre Sa
Annual Report
The report highlights Pierre Fabre Laboratories' achievements in 2024, including surpassing the –3 billion revenue milestone driven by international growth and oncology innovations. The company advanced its 'Conquest 2025' strategic plan, focusing on therapeutic innovation, operational excellence, and ecological transition. Key environmental milestones include a 25% reduction in greenhouse gas emissions (Scopes 1 and 2) and a 37% reduction in water consumption in France compared to baseline years. Additionally, the company invested –219 million in R&D, with a strong focus on oncology, and continued to support access to healthcare through the Fondation Pierre Fabre.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Renewable Energy
Women in Management
Net Zero Target